CN Patent

CN105153307A — 抗表皮生长因子受体(egfr)的抗体及其用途

Assigned to Merrimack Pharmaceuticals Inc · Expires 2015-12-16 · 10y expired

What this patent protects

公开了抗EGFR抗体、包含抗EGFR抗体组合的治疗组合物以及使用此类抗体和组合物治疗EGFR相关病症(例如，癌症)的方法。

USPTO Abstract

公开了抗EGFR抗体、包含抗EGFR抗体组合的治疗组合物以及使用此类抗体和组合物治疗EGFR相关病症(例如，癌症)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN105153307A
Jurisdiction
CN
Classification
—
Expires
2015-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Merrimack Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.